Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | DBH | P09172 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.46 |
| ▸ | CHRNG | P07510 | 2/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | CHRND | Q07001 | 2/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12780290 | 0.85 | GAA (0.53) | HDAC1HDAC6GAAKDM4EDBH | |
| SCHEMBL3860137 | 0.84 | CHRNA1 (0.62) | GAAKDM4EDBHRECQLCHRNA1 | |
| SCHEMBL3670046 | 0.82 | KDM4E (0.59) | GAAKDM4EDBHRECQLCHRNA1 | |
| SCHEMBL4609777 | 0.81 | KDM4E (0.69) | GAAKDM4EDBHRECQLCHRNA1 | |
| SCHEMBL7247767 | 0.79 | GAA (0.52) | HDAC1HDAC6GAAKDM4EDBH | |
| SCHEMBL19769164 | 0.79 | GAA (0.52) | HDAC6GAAKDM4EDBHRECQL | |
| SCHEMBL17275631 | 0.79 | GAA (0.52) | HDAC1HDAC6GAAKDM4EDBH | |
| SCHEMBL18997244 | 0.79 | HDAC1 (0.47) | HDAC1HDAC6CHRNA1CHRNGCHRNB1 | |
| SCHEMBL12438206 | 0.78 | GAA (0.50) | GAAKDM4EDBHRECQLCHRNA1 | |
| SCHEMBL18290840 | 0.78 | GAA (0.50) | HDAC1HDAC6GAAKDM4EDBH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-06 | — | — | US | disclosed |
| US-9333202-B2 | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | HDAC1 2341/4885HDAC6 1732/4885GAA 303/4885 |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | HDAC1 2341/4885HDAC6 1732/4885GAA 303/4885 |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | HDAC1 186/4885HDAC6 100/4885GAA 1697/4885 |
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | HDAC1 433/4885HDAC6 167/4885GAA 195/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | HDAC1 203/4885HDAC6 140/4885GAA 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.